The Medical Letter on Drugs and Therapeutics
In Brief: Shingrix for Immunocompromised Adults
Download PDF:   US English
Med Lett Drugs Ther. 2021 Aug 23;63(1631):129
Principal Faculty
  • Mark Abramowicz, M.D., President: no disclosure or potential conflict of interest to report
  • Jean-Marie Pflomm, Pharm.D., Editor in Chief: no disclosure or potential conflict of interest to report
  • Brinda M. Shah, Pharm.D., Consulting Editor: no disclosure or potential conflict of interest to report
Additional Contributor(s)
  • Michael Viscusi, Pharm.D., Associate Editor: no disclosure or potential conflict of interest to report
Upon completion of this activity, the participant will be able to:
  1. Discuss the data supporting the use of the adjuvanted, recombinant varicella zoster virus vaccine (Shingrix) in immunocompromised patients.
 Select a term to see related articles  Shingles   Shingrix   vaccines   varicella zoster virus 

The FDA has licensed the adjuvanted, recombinant varicella zoster virus (VZV) vaccine Shingrix (GSK) for prevention of herpes zoster (shingles) in adults of any age who are or will be at elevated risk because of disease- or therapy-induced immunodeficiency or immunosuppression. Shingrix has been licensed for herpes zoster prevention in adults ≥50 years old since 2017.1 It is the only VZV vaccine currently available in the US; Zostavax, a live-attenuated VZV vaccine, was withdrawn from the market in 2020.

FDA licensure of Shingrix for the new indication was based on the results of two studies: a randomized, placebo-controlled trial in 1846 immunocompromised adults ≥18 years old who had received an autologous hematopoietic stem cell transplant within the previous 50-70 days, and a post-hoc analysis of a similar trial in 569 adults who were receiving immunosuppressive therapy for hematologic malignancies. In both trials, Shingrix significantly decreased the incidence of herpes zoster occurring ≥1 month after the second dose compared to placebo (see Table 1).2,3

Adverse effects of Shingrix in immunocompromised persons appear to be similar to those in healthy older adults. Myalgia, fatigue, headache, shivering, fever, GI symptoms, and injection-site pain, redness, and swelling are common. Severe local reactions preventing normal daily activities can occur.1,4 In a postmarketing observa-tional study in adults ≥65 years old, use of Shingrix was associated with an increased risk of Guillain-Barré syndrome in the 6 weeks after vaccination.5

In healthy older adults, Shingrix is typically given as two 0.5-mL doses administered intramuscularly 2-6 months apart. For immunocompromised patients who would benefit from a shorter vaccination schedule, the second dose can be given as early as 1 month after the first. Updated recommendations from the Advisory Committee on Immunization Practices (ACIP) on use of the vaccine in immunocompromised persons were not available at press time.

© The Medical Letter, Inc. All Rights Reserved.
The Medical Letter, Inc. does not warrant that all the material in this publication is accurate and complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.
This article has been freely provided.
arrow to previous article
arrow to next article